Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treament of type 2 diabetes

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 4, 2003, Pages 499-510

  Augustyns, Koen ^a   Van der Veken, Pieter ^a   Senten, Kristel ^a   Haemers, Achiel ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Dipeptidyl peptidase (DPP) IV; DPP IV inhibitors; Glucagon like peptide 1 (GLP 1); Incretin hormones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; 7 BENZYL 1,3 BISMETHYL 8 (1 PIPERAZINYL)XANTHINE; ACARBOSE; ALKENE DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FE 999011; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCYLPROLYLISOLEUCYLTHIAZOLIDIDE; INSULIN; ISOLEUCINE THIAZOLIDIDE; ISOLEUCYLTHIAZOLIDIDE; METFORMIN; NITRILE; ORAL ANTIDIABETIC AGENT; PHOSPHONIC ACID DERIVATIVE; PYRROLIDINE DERIVATIVE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; THIOAMIDE; TSL 225; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYLPYRROLIDIDE; VILDAGLIPTIN; XANTHINE DERIVATIVE;

DRUG HALF LIFE; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE INHIBITION; HUMAN; MEDICAL LITERATURE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; PATHOLOGY; PREVALENCE; PROTEIN FUNCTION; RAT; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0037397603     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.4.499     Document Type: Review

References (62)

1. BAILEY CJ: Potential new treatments for Type 2 diabetes. Trends In Pharmacol. Sci. (2000) 21:259-265.
2. ZHANG BB, MOLLER DE: New approaches in the treatment of Type 2 diabetes. Curr. Opin. Chem. Biol. (2000) 4:461-467.
3. HOLST JJ, ORSKOV C: Incretin hormones - an update. Scand. J. Clin. Lab. Invest. (2001) 61(Suppl.234):75-86.
4. CREUTZFELDT W: The entero-insular axis in Type 2 diabetes - incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes (2001) 109(Suppl.2):S288-S303.
5. NAUCK MA, STOCKMANN F, EBERT R, CREUTZFELDT W: Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia (1986) 29:46-52.
6. NAUCK MA, HEIMESAAT MM, ÖRSKOV C, HOLST JJ, EBERT R, CREUTZFELDT W: Preserved incretin activity of GLP-1 [7-36 amide] but not of synthetic human GIP in patients with Type-2-diabetes mellitus. J. Clin. Invest. (1993) 91:301-307.
7. RACHMAN J, BARROW BA, LEVY JC, TURNER RC: Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia (1997) 40:205-211.
8. NAUCK MA, WOLLSCHLAGER D, WERNER J, HOLST JJ, ORSKOV C, CREUTZFELDT W: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia (1996) 39:1546-1553.
9. KNUDSEN LB, PRIDAL L: Glucagon-like peptide-1-[9-36] amide is a major metabolite of glucagon-like peptide-1-[7-36] amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. (1996) 318:429-435.
10. DE MEESTER I, KOROM S, VAN DAMME J, SCHARPE S: CD26, let it cut or cut it down. Immunol. Today (1999) 20:367-375.
11. DE MEESTER I, DURINX C, BAL G et al.: Natural substrates of dipeptidyl peptidase IV. Adv. Exp. Med. Biol. (2000) 477:67-87.
12. MENTLEIN R: Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. (1999) 85:9-24.
13. AUGUSTYNS K, BAL G, THONUS G et al.: The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr. Med. Chem. (1999) 6:311-327.
14. VILLHAUER EB, COPPOLA GM, HUGHES TE: Chapter 19. DPP-IV inhibition and therapeutic potential. Ann. Rep. Med. Chem. (2001) 36:191-200.
15. MENTLEIN R, GALLWITZ B, SCHMIDT E: Dipeptidyl-peptidase IV hydrolyses gastric inhihitory polypeptide, glucagon-like peptide-1[7-36]amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. (1993) 214:829-835.
16. KIEFFER TJ, MCINTOSH CHS, PEDERSON RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1998) 136:3585-3596.
17. HANSEN L, DEACON CF, ORSKOV C, HOLST JJ: Glucagon-like peptide-1-[7-36] amide is transformed to glucagon-like peptide-1-[9-36]amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology (1999) 140:5356-5363.
18. 2-terminus in Type II diabetic patients and in healthy subjects. Diabetes (1995) 44:1126-1131.
19. HOLST JJ: Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr. Med. Chem. (1999) 6:1005-1017.
20. DRUCKER DJ: Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr. Pharm. Des. (2001) 7:1399-1412.
21. DEACON CF, HUGHES TE, HOLST JJ: Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes (1998) 47:764-769.
22. MARGUET D, BAGGIO L, KOBAYASHI T et al.: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Nat. Acad. Sci. USA (2000) 97:6874-6879.
23. NAGAKURA T, YASUDA N, YAMAZAKI K et al.: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient fischer rats. Biochem. Biophys. Res. Comm. (2001) 284:501-506.
24. YASUDA N, NAGAKURA T, YAMAZAKI K, INOUE T, TANAKA I: Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sci (2002) 71:227-238.
25. SEDO A, MALIK R: Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim. Biophys. Acta (2001) 1550:107-116.
26. SCHÖN E, BORN I, DEMUTH HU et al.: Dipeptidyl peptidase IV in the immune system: effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol. Chem. Hoppe Seyler (1991) 372:305-311.
27. AUGUSTYNS K, LAMBEIR AM, BORLOO M et al.: Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. Eur. J. Med. Chem. (1997) 32:301-309.
28. ASHWORTH DM, ATRASH B, BAKER GR et al.: 2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. (1996) 6:1163-1166.
29. LI J, WILK E, WILK S: Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). Arch. Biochem. Biophys. (1995) 323:148-154.
30. SUDRE B, BROQUA P, WHITE RB et al.: Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes (2002) 51:1461-1469.
31. ASHWORTH DM, ATRASH B, BAKER GR et al.: 4-cyanothiazolididies as very potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. (1996) 6:2745-2748.
32. GUTHEIL WG, BACHOVCHIN WW: Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. Biochemistry (1993) 32:8723-8731.
33. FLENTKE GR, MUNOZ E, HUBER BT, PLAUT AG, KETTNER CA, BACHOVCHIN WW: Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T cell function. Proc. Natl. Acad. Sci. USA (1991) 88:1556-1559.
34. DEMUTH HU, NEUMANN U, BARTH A: Reactions between dipeptidyl peptidase IV and diacyl hydroxylamines: mechanistic investigations. J. Enzym. Inhibit. (1989) 2:239-248.
35. BODUSZEK B, OLEKSYSZYN J, KAM CM, SELZLER J, SMITH RE, POWERS JC: Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. J. Med. Chem. (1994) 37:3969-3976.
36. LAMBEIR AM, BORLOO M, DE MEESTER I et al.: Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV. Biochim. Biophys. Acta (1996) 1290:76-82.
37. DE MEESTER I, BELYAEV A, LAMBEIR AM et al.: In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine). Biochem. Pharmacol. (1997) 54:173-179.
38. STÖCKEL MA, MRESTANI-KLAUS C, STIEBITZ B, DEMUTH HU, NEUBERT K: Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases. Biochim. Biophys. Acta (2000) 1479:15-31.
39. SENTEN K, VAN DER VEKEN P, BAL G et al.: Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:2825-2828.
40. HUGHES TE, MONE MD, RUSSELL ME, WELDON SC, VILLHAUER EB: NVP-DPP728: (1-[[[2-[(5-cyanopyridin-2-yl) amino]ethyl]amino]acetyl]-2-cyano-(S)-ryrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry (1999) 38:11597-11603.
41. VILLHAUER EB, BRINKMAN JA, NADERI GB et al.: 1-[2-[(5-cyanopyridin-2-yl) amino]-ethylamino]acetyl-2-(S)-pyrrolidine-carbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. (2002) 45:2362-2365.
42. HUGHES TE, RUSSELL ME, BOLOGNESE L: NVP-LAF237, a highly selective and long-acting dipeptidyl peptidase IV inhibitor. Diabetes (2002) 51(Suppl.2):A67.
43. ZHAO K, LIM DS, FUNAKI T, WELCH JT. Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1- fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg. Med. Chem. (2003) 11:207-215.
44. LIN J, TOSCANO PJ, WELCH JT: Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics. Proc. Natl. Acad. Sci. USA (1998) 95:14020-14024.
45. BELYAEV A, ZHANG XM, AUGUSTYNS K et al.: Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. J. Med. Chem. (1999) 42:1041-1052.
46. NO AUTHORS LISTED: BDPX. Drug Data Report (2002) 24:620.
47. YAMADA M, OKAGAKI C, HIGASHIJIMA T, TANAKA S, OHNUKI T, SUGITA T: A potent dipeptide inhibitor of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. (1998) 8:1537-1540.
48. OHNUKI T, YAMADA M, SUGITA T: Novel dipeptidyl peptidase IV inhibitors with antiarthritic effects. Drugs of the Future (1999) 24:665-670.
49. COPPOLA GM, ZHANG YL, SCHUSTER HF, RUSSELL ME, HUGHES TE: 1-aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:1555-1558.
50. PAULY RP, DEMUTH HU, ROSCHE F et al.: Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor ile-thiazolidide. Metabolism (1999) 48:385-389.
51. PEDERSON RA, WHITE HA, SCHLENZIG D, PAULY RP, MCINTOSH CHS, DEMUTH HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes (1998) 47:1253-1258.
52. POSPISILIK JA, STAFFORD SG, DEMUTH HU et al.: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes (2002) 51:943-950.
53. SORBERA LA, REVEL L, CASTANER J: P32/98. Antidiabetic, dipeptidyl-peptidase IV inhibitor. Drugs of the Future (2001) 26:859-864.
54. DEACON CF, DANIELSEN P, KLARSKOV L, OLESEN M, HOLST JJ: Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes (2001) 50:1588-1597.
55. AHREN B, HOLST JJ, MARTENSSON H, BALKAN B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. (2000) 404:239-245.
56. BALKAN B, KWASNIK L, MISERENDINO R, HOLST JJ, LI X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 [7-36 amide] concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia (1999) 42:1324-1331.
57. AHREN B, SIMONSSON E, LARSSON H et al.: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in Type 2 diabetes. Diabetes Care (2002) 25:869-875.
58. DEACON CF, WAMBERG S, BIE P, HUGHES TE, HOLST JJ: Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol. (2002) 172:355-362.
59. REIMER MK, HOLST JJ, AHREN B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. (2002) 146:717-727.
60. MITANI H, TAKIMOTO M, HUGHES TE, KIMURA M: Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn. J. Pharmacol (2002) 88:442-450.
61. MITANI H, TAKIMOTO M, KIMURA M: Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity. Jpn. J. Pharmacol. (2002) 88:451-458.
62. RASMUSSEN HB, BRANNER S, WIBERG FC, WAGTMANN N: Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. (2003) 10:19-25.